INMB
INMB
NASDAQ · Biotechnology

Inmune Bio Inc

$1.05
-0.05 (-4.55%)
Financial Highlights (FY 2026)
Revenue
47.1K
Net Income
-43,663,336
Gross Margin
—
Profit Margin
-91,866.0%
Rev Growth
-48.7%
D/E Ratio
—
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin — — 61.9% 61.9%
Operating Margin -94,766.0% -85,290.1% 16.6% 15.4%
Profit Margin -91,866.0% -87,272.7% 15.9% 12.3%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 47.1K 91.7K 11.20M 11.67M
Gross Profit — — 6.93M 7.23M
Operating Income -44,604,460 -78,222,942 1.85M 1.79M
Net Income -43,663,336 -76,572,491 1.78M 1.44M
Gross Margin — — 61.9% 61.9%
Operating Margin -94,766.0% -85,290.1% 16.6% 15.4%
Profit Margin -91,866.0% -87,272.7% 15.9% 12.3%
Rev Growth -48.7% -48.7% +3.1% +2.1%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 11.90M 13.58M
Total Equity — — 32.54M 29.49M
D/E Ratio — — 0.37 0.46
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -44,962,433 -83,231,315 2.32M 2.58M
Free Cash Flow — — 977.1K 708.5K